$LQDA

Khindri Sanjeev sold $271K of LQDA

Khindri Sanjeev (Chief Development Officer) sold 4,134 shares of Liquidia Corp (LQDA) at $65.46 ($0.27M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khindri Sanjeev
Published Jun 10, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure adds incremental information about insider liquidity/positioning but does not introduce new company fundamentals (no guidance, trial results, or regulatory actions).

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article lacks context on total insider activity, prior sales cadence, and whether the sale was for diversification/tax—so the signal-to-noise is low.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-10; transaction dated 2026-06-08.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an insider open-market sale by CDO Khindri Sanjeev: 4,134 shares sold at $65.46 on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive value; the article provides no new operational/clinical/regulatory catalyst.

Market effects

Minimal; single-company insider sale without new sector/regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term risk; traders may use it as a sentiment check rather than a fundamental signal.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Khindri Sanjeev

    Chief Development Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient